IL173805A0 - Method and compositions for treating herpes infections - Google Patents

Method and compositions for treating herpes infections

Info

Publication number
IL173805A0
IL173805A0 IL173805A IL17380506A IL173805A0 IL 173805 A0 IL173805 A0 IL 173805A0 IL 173805 A IL173805 A IL 173805A IL 17380506 A IL17380506 A IL 17380506A IL 173805 A0 IL173805 A0 IL 173805A0
Authority
IL
Israel
Prior art keywords
compositions
treating herpes
herpes infections
infections
treating
Prior art date
Application number
IL173805A
Other languages
English (en)
Original Assignee
Talecris Biotherapeutics Inc
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talecris Biotherapeutics Inc, Bayer Healthcare Llc filed Critical Talecris Biotherapeutics Inc
Publication of IL173805A0 publication Critical patent/IL173805A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL173805A 2003-09-05 2006-02-19 Method and compositions for treating herpes infections IL173805A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/656,781 US6984492B2 (en) 2003-09-05 2003-09-05 Methods and compositions for treating herpes infections
PCT/US2004/028559 WO2005025617A2 (en) 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections

Publications (1)

Publication Number Publication Date
IL173805A0 true IL173805A0 (en) 2006-07-05

Family

ID=34226428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173805A IL173805A0 (en) 2003-09-05 2006-02-19 Method and compositions for treating herpes infections

Country Status (13)

Country Link
US (3) US6984492B2 (enExample)
EP (1) EP1663309A2 (enExample)
JP (1) JP2007504268A (enExample)
KR (1) KR20060107509A (enExample)
CN (1) CN1845756A (enExample)
AU (1) AU2004272001A1 (enExample)
BR (1) BRPI0414139A (enExample)
CA (1) CA2537360A1 (enExample)
IL (1) IL173805A0 (enExample)
NO (1) NO20061184L (enExample)
NZ (1) NZ546303A (enExample)
WO (2) WO2005023303A1 (enExample)
ZA (1) ZA200602738B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2248825T3 (pl) 2009-05-04 2013-04-30 Ribovax Biotechnologies Sa Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
WO2014070786A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
RU2703903C2 (ru) * 2014-06-26 2019-10-22 Хайдельберг Иммунотерапьютикс Гмбх Местное применение антитела к hsv
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017083681A1 (en) 2015-11-13 2017-05-18 The University Or North Carolina At Chapel Hill Optimized crosslinkers for trapping a target on a substrate
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020097528A1 (en) * 2018-11-08 2020-05-14 The Board Of Trustees Of The University Of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4717564A (en) * 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
RU2051054C1 (ru) 1992-04-14 1995-12-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Способ получения препарата противогерпетического иммуноглобулина человека
US5681565A (en) 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
WO1998046240A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
JP2007504268A (ja) 2007-03-01
BRPI0414139A (pt) 2006-10-31
CN1845756A (zh) 2006-10-11
US6984492B2 (en) 2006-01-10
KR20060107509A (ko) 2006-10-13
US20090232798A1 (en) 2009-09-17
US20060198848A1 (en) 2006-09-07
WO2005025617A2 (en) 2005-03-24
WO2005025617A3 (en) 2005-05-26
CA2537360A1 (en) 2005-03-24
NZ546303A (en) 2009-03-31
EP1663309A2 (en) 2006-06-07
US20050053605A1 (en) 2005-03-10
AU2004272001A1 (en) 2005-03-24
ZA200602738B (en) 2008-06-25
NO20061184L (no) 2006-06-01
WO2005023303A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
EP2671581B8 (en) Compositions and methods for treating cancer
AP2089A (en) Compositions and methods for combination antiviraltherapy
PT2286663T (pt) Métodos e composições para tratar infestação de ectoparasitas
IL164000A0 (en) Compositions and methods for treating emphysema
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-S
PT1471902E (pt) Métodos para o tratamento da perda de audição
GB0609689D0 (en) Non-nucleotide compositions and method for treating pain
IL160010A0 (en) Methods and compositions for treating fungal infections
AU2003297573A8 (en) Compositions and methods for treating transplants
AU2003212894A1 (en) Compositions and methods for treating diarrhea
SG118236A1 (en) Compositions and methods for treating coronavirus infection and SARS
ZA200602738B (en) Methods and compositions for treating herpes infections
EP1684771A4 (en) COMPOSITION AND METHOD
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
EP1677754A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE EFFECTIVE DYSFUNCTION
AU2003296963A8 (en) Methods and compositions for treating and preventing ear infections
AU2003238905A1 (en) Surface treating compositions and methods for using same
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
AU2003295574A8 (en) Method and compositions for temporarily incapaciting subjets
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
ZA200602275B (en) Composition and method for treating bezoar and trichobezoar
AU2003210474A8 (en) Composition and method for inhibiting hypersensitivity
AU2003275433A8 (en) Compositions and methods for treating pain
EP1594473A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF AGE-RELATED DISEASES
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity